

Relevance of *vacA* Genotypes of *Helicobacter pylori* to *cagA* Status and Its Clinical Outcome

Sill Moo Park, M.D., Joongwon Park, M.D., Jae Gyu Kim, M.D.
and Byung Chul Yoo, M.D.

Department of Internal Medicine, College of Medicine,
Chung-Ang University, Seoul, Korea

Background : Determination of *vacA* mosaicism may be important because specific *Helicobacter pylori vacA* genotype can be used to predict different clinical outcome. The aim of this study was to assess the relationship of *vacA* genotypes of *Helicobacter pylori* to *cagA* status and its development of peptic ulcer diseases in Korean patients.

Methods : Gastric biopsy specimens were obtained from 53 patients with gastric ulcer (GU), 57 with duodenal ulcer (DU) and 26 with chronic gastritis (CG) patients; all patients were infected with *Helicobacter pylori*. Bacterial mRNAs in the gastric mucosa were amplified by RT-PCR, using synthetic oligonucleotide primers specific for the *vacA* and the *cagA* gene. Patients with *vacA s1* subtype were further examined to determine whether they had *s1a* or *s1b* subtype.

Results : There was no correlation in frequency of *vacA s1* and/or *s1a* genotype between CG and either GU or DU, as the *vacA s1* and *s1a/m1* were present in the majority of strains independent of clinical status (*s1* ; 100.0% versus 94.3 % or 93.0 % and *s1a/m1* ; 76.9% versus 62.3% or 64.9%, respectively). Likewise, there was no difference in the prevalence of the *cagA* gene between CG and either GU or DU patients (92.3% versus 90.6% or 98.2%, respectively). In addition, the *cagA*-negative status did not predict the presence of *vacA s2* genotype.

Conclusion : These results strongly suggest that either *cagA* or *vacA s1* and/or *s1a* is not proved to be a useful marker to distinguish disease-specific *Helicobacter pylori* strains for the development of peptic ulcer diseases in Korean patients.

Key Words : *vacA*, *cagA*, Chronic gastritis, Peptic Ulcer

Introduction

Helicobacter pylori (*H. pylori*) infection may induce chronic gastritis, peptic ulcer diseases, gastric adenocarcinoma and gastric MALT lymphoma. However, it has not been solved why most subjects infected with *H. pylori* are not affected by peptic ulcer diseases or gastric carcinoma. The cause of these different clinical outcomes of *H. pylori* infection remains unclear and may

include host and environmental factors¹⁻³⁾ and differences in the prevalence or expression of bacterial virulence factors. Infection with certain strains of *H. pylori* is related to more severe morbidity, whereas other variants appear less pathogenic⁴⁻⁹⁾. Two characteristics previously linked to pathogenicity are production of a vacuolating cytotoxin and possession of *cagA* gene. Both of these characteristics have been known to be significant risk factors for developing more serious gastroduodenal diseases^{5,7,10-12)}. Recently however, there have been increasing reports that the *cagA* gene is not proved to be a useful marker to distinguish disease-specific *H. pylori* strains for the development of peptic ulcer diseases¹³⁻¹⁶⁾.

Address reprint requests to : Sill Moo Park, M.D., Ph.D.,
Department of Internal Medicine, Chung-Ang University,
Yong-San Hospital, 65-207 Hangang-Ro 3-Ka, Yongsan-Ku,
Seoul 40-757, Korea

Approximately 50% of clinical isolates of *H. pylori* produce VacA protein that causes vacuolar degeneration in several mammalian cell lines in culture, while all strains have the gene encoding the vacuolating cytotoxin, VacA¹⁷⁾. Infection by a subset of *H. pylori* strains, referred to as type I, which contain a pathogenicity island in the chromosome and which are strongly toxigenic, can cause more severe pathology than type II, non-toxigenic strains¹²⁾. Furthermore, intragastric administration of highly purified VacA caused epithelial erosions and ulcerations similar to those seen in mice infected with type I *H. pylori* strains¹⁸⁾. The genetic sequence of the *vacA* varies markedly between type I and type II strains of *H. pylori* especially in the region encoding the signal sequence and the mid-region of the gene¹⁸⁾. This mosaic pattern of *vacA* alleles is similar or dissimilar between bacterial strains. All combinations of the three signal sequence types (s1a, s1b, or s2) and two mid-region types (m1 or m2) are found, implying horizontal acquisition of genetic elements and recombination between *H. pylori* strains in vivo¹⁸⁾. Classification of *vacA* mosaicism may be important because specific *H. pylori vacA* genotypes can be used to predict different clinical status of *H. pylori* infection. Atherton et al.^{8,19)} reported that s1 and/or s1a genotype was more frequently associated with duodenal ulcer disease and also associated with more severe infiltration of neutrophils and lymphocytes in human gastric antral mucosa than s1b or s2 strains. They also found that *cagA* status was closely associated with the *vacA* s1 or the s2 allele. For example, 88% of USA strains with *vacA* s1 allele were found to be *cagA*-positive, and all 19 strains with *vacA* s2 allele were *cagA*-negative.

The present study aimed to determine the relevance of *vacA* genotypes of *H. pylori* to *cagA* status and its development of peptic ulcer diseases in Korean patients infected with *H. pylori*.

MATERIALS AND METHODS

1. Population Studied

The study population was made up of 136 patients (107 males and 29 females; mean age, 46.6 years; range 17 - 81). One hundred and ten patients were endoscopically and histologically confirmed to have benign gastric ulcer (GU, 53 patients) or duodenal ulcer (DU, 57 patients) in addition to being infected with *H. pylori*. The control group consisted of 26 patients with chronic

gastritis (CG) who were also infected with *H. pylori*. Patients were excluded if they had a history of gastric surgery, active gastrointestinal bleeding or exposure to steroids or NSAIDs, H₂-receptor antagonists, proton pump inhibitors or antimicrobial agents within 30 days prior to this study. Patients with any other chronic illness were also excluded.

2. Endoscopy and diagnosis of *H. pylori* infection

Gastroscopic examination was performed and the endoscopic findings were recorded. Biopsy specimens in each patient were obtained from gastric antrum within 2 cm proximal to the pylorus and from gastric midbody. Histological confirmation of *H. pylori* infection was done by the Warthin-Starry silver staining method. Individual mucosal specimen was evaluated by a single pathologist who was unaware of the PCR results. Microaerophilic culture under 37 °C and rapid urease test were also performed in each patient. The remaining biopsy specimens from gastric antrum and midbody in each patient were frozen at -70 °C for RNA extraction and RT-PCR to detect the presence of *H. pylori* genes. Patients were classified as *H. pylori*-positive when the culture was positive or if at least three of the four examinations, such as rapid urease test, histologic examination, RT-PCR examination for the presence of *ureA* and 16S-rRNA, gave positive results for *H. pylori*.

3. Detection of *H. pylori cagA*, *vacA* and s1a subtype expression

Detection of *H. pylori ureA*, *cagA* and 16S-rRNA of genomic DNA from clinical isolates and of cDNA from gastric mucosal biopsy specimens was performed by PCR and RT-PCR amplification by using oligonucleotide primers described in detail previously¹⁵⁾. In brief, amplification of the *cagA* gene was done using the previously described primers F1(5'-GATAACAGGCAAGCTTTTGAGG-3') and B1(5'-CTGCAAAAGATTGTTTGGCAGA-3') with annealing at 55 °C to amplify a 349-bp product from the middle of the *cagA*.

Twenty-eight histology-positive patients (10 GU, 10 DU, 8 CG) were selected to test *cagA* and *vacA* s1a allele both from clinical isolates and from the mucosa in order to confirm that the expression of each gene in the gastric mucosa reflected the genotype of the infecting organism. After confirming these results, RT-PCR amplifications were done for *ureA*, 16S-rRNA, *cagA*, and *vacA*

genotypes in the remaining patients using mucosal biopsy specimens.

4. PCR-based *vacA* genotyping

Typing of the *vacA* signal sequence and mid-regions was performed by using oligonucleotide primer pairs based on published data¹⁷⁾. The primer pairs VA1-F/VA1-R(5'-ATGGAATACAACAAACACAC-3' and 5'-CTGCT-TGAATGCGCAAAC-3') and SS2-F/VA1-R(5'-GCTAACAC-GCCAAATGATCC-3' and VA1-R as above) were used to distinguish between s1 and s2. Primer pairs VA3-F/VA3-R(5'-GGTCAAATGCGGTCATGG-3' and 5'-CCA-TGGTACCTGTAGAAAC-3') and VA4-F/VA4-R(5'-GGAG-CCCCAGGAAACATTG-3' and 5'-CATAACTAGCGCCT-TGCAC-3') were used to amplify the m1 and m2 mid-regions, respectively. Each strain was typed as s1a or s1b by performing two separate RT-PCRs, each using one primer specific to the signal sequence type SS1-F(5'-GTCAGCATCACACCGCAAC-3'), SS3-F(5'-AGCG-CCATACCGCAAGAG-3'), and one conserved primer(VA1-R as above). Thermal cycling of each set of primers(0.5 M each) was performed at 95 °C for 1 min, 52 °C for 1 min, and 72 °C for 1 min, for a total of 35 cycles.

5. Statistical Analysis

Pearson's chi-square test was used to determine the significance of difference among three groups with a difference in p value less than 0.05 being considered significant.

RESULTS

Twenty-eight histology-positive cases which were also positive for the *ureA* gene, rapid urease test and culture were selected in order to confirm that RT-PCR detection of *cagA* and expression of *vacA* alleles in the gastric biopsy specimen reflected the genotype of the infecting organism. Complementary DNA was prepared from the corresponding gastric biopsy specimens from the same patient whose specimen was used as the template for PCR. With genomic DNAs, the *cagA* was positive in 26 (92.9%) and the *vacA* s1a was positive in 24 (82.8%) out of 28 isolates. Each of the 26 and the 24 corresponding gastric biopsy specimens was also positive for *cagA* and s1a by RT-PCR. Neither the *cagA* nor the *vacA* s1a gene was found in the remaining 2 and 4 corresponding gastric mucosa whose genomic DNAs did not possess either *cagA* or *vacA* s1a gene. These results suggest

that *cagA* and *vacA* s1a of bacterial genomic DNA detected by PCR are identical with those from the gastric mucosal biopsy detected by RT-PCR. After confirming these results, RT-PCR amplification was done for *ureA*, 16S-rRNA, *cagA* gene and *vacA* signal sequence and mid-region alleles in the remaining patients using mucosal biopsy specimens.

1. *vacA* Genotyping

Signal sequence and mid-region genotypes of the *vacA* gene were obtained in all patients. One hundred and twenty nine(94.9%) out of 136 mucosal specimens had the s1 allele, of which 99(76.7%) had the s1a subtype, whereas 30(23.3%) had the s1b subtype. The remaining seven(5.1%) specimens had s2 subtype. Mid-region subtypes such as the *vacA* m1 and m2 were found in 118(86.8%) and 18(13.2%) out of 136 mucosal specimens, respectively. Overall, 90(66.2%) strains were classified into the s1a/m1, 9(6.6%) were s1a/m2, 28(20.6%) were s1b/m1, 2(1.5%) were s1b/m2, and 7(5.1%) strains were s2/m2(Table 1).

Table 1. *vacA* genotype status of *H. pylori* strains in gastric biopsy specimens from 136 patients

Genotype Status	Clinical Status			Total (n=136)
	Peptic Ulcer		Chronic Gastritis (n=26)	
	Gastric Ulcer (n=53)	Duodenal Ulcer (n=57)		
VacA				
s1	50(94.3%)	53(93.0%)	26(100.0%)	129(94.9%)
s1a	34(68.0%)	44(83.0%)	21(80.8%)	99(76.7%)
s1b	16(32.0%)	9(17.0%)	5(19.2%)	30(23.3%)
s2	3(5.7%)	4(7.0%)	0	7(5.1%)
s1a/m1	33(62.2%)	37(64.9%)	20(76.9%)	90(66.2%)
s1a/m2	1(1.9%)	7(12.3%)	1(3.9%)	9(6.6%)
s1b/m1	15(28.3%)	8(14.0%)	5(19.2%)	28(20.6%)
s1b/m2	1(1.9%)	1(1.8%)	0	2(1.5%)
s2/m2	3(5.7%)	4(7.0%)	0	7(5.1%)

The prevalence of *vacA* genotype was not different between chronic gastritis and either gastric ulcer or duodenal ulcer patients.

2. Association of *vacA* genotype with *cagA* gene

One hundred and twenty eight strains(94.1%) were positive for *cagA* gene by RT-PCR methods. Eight patients(5 GU patients, 1 DU, and 2 CG) were negative for *cagA*. The prevalence of *cagA*-positive was not different

between patients with CG and patients with either GU or DU (92.3% vs. 90.6% and 98.2%, respectively). There was no correlation in the prevalence between the *cagA* and the *vacA* s1a, because *vacA* s1a genotype was found in 31(64.6%) out of 48 GU patients, 43(76.8%) out of 56 DU, and 20(83.3%) out of 24 CG patients who were infected with *cagA*-positive *H. pylori* strains (Table 2 and 3). These results do not support the hypothesis that *H. pylori* strain possessing the *cagA* gene and the *vacA* s1a allele is a useful marker for the discrimination of specific clinical status. Likewise, the presence of *cagA*-negative status did not predict the presence of *vacA* s2 genotype because 7 out of 8 *cagA*-negative strains were the s1 (6 isolates with s1a and 1 with s1b) and 6 isolates with the s2 subtype were *cagA*-positive.

3. Association of *vacA* genotypes with the disease status

All of the CG patients had *vacA* s1 allele genotype. Twenty-one patients (80.8%) were positive for the s1a and 5 patients (19.2%) were positive for the s1b subtype. Fifty patients (94.3%) with GU had s1 allele, of which 34 (68.0%) had s1a and 16 (32.0%) had s1b subtype. In DU patients, 93.0% (53 out of 57 patients) had s1 genotype, consisting of 83.0% (44 out of 53) with s1a and 17.0% (9 out of 53) with s1b subtype.

Table 2. Relationship between *vacA* genotypes and *cagA* status

	No. specimens	<i>vacA</i> type				
		s1a/m1	s1a/m2	s1b/m1	s1b/m2	s2/m2
<i>cagA</i> positive	128	85(66.4%)	8(6.2%)	27(21.1%)	2(1.6%)	6(4.7%)
<i>cagA</i> negative	8	5(62.5%)	1(12.5%)	1(12.5%)	0	1(12.5%)

There was no correlation between *cagA* status and *vacA* genotypes.

Table 3. Relationship between *vacA* genotypes or the prevalence of *cagA* and disease status

Disease Status	No. Studied	<i>cagA</i>		<i>vacA</i> type				
		Status	No. patients	s1a/m1	s1a/m2	s1b/m1	s1b/m2	s2/m2
CG	26	Positive	24(92.3%)	19(79.1%)	1(4.2%)	4(16.7%)	0	0
		Negative	2(7.7%)	1(50.0%)	0	1(50.0%)	0	0
GU	53	Positive	48(90.6%)	30(62.5%)	1(2.1%)	14(29.1%)	1(2.1%)	2(4.2%)
		Negative	5(9.4%)	3(60.0%)	0	1(20.0%)	0	1(20.0%)
DU	57	Positive	56(98.2%)	36(64.3%)	7(12.5%)	8(14.3%)	1(1.8%)	4(7.1%)
		Negative	1(1.8%)	1(100.0%)	0	0	0	0

CG : Chronic gastritis, GU : Gastric ulcer, DU : Duodenal ulcer

There was no correlation between *vacA* genotypes or *cagA* and disease status .

DISCUSSION

Our study demonstrated that *vacA* gene was found in all *H. pylori* obtained from 136 mucosal specimens and all combinations of the signal sequence and the mid-region subtypes except for s2/m1 were detected. Infection with vacuolating cytotoxin producing *H. pylori* has been reported to be associated with particular gastro-duodenal diseases^{8,19,20}. Several reports from Europe and the United States revealed that the positive rate of *vacA* s1 genotype was significantly correlated with the development of peptic ulcer diseases. These studies also showed that strains with *vacA* s1a allele were more likely associated with past or present ulcers than those with nonulcer dyspepsia^{8,19,21,22}. However, our results showed that the prevalence of the s1a subtype was not statistically different between CG and either GU or DU (CG 83.3% vs. GU 64.6% or DU 76.8%). These results were substantially different from the results obtained from Western countries. Despite the overall higher prevalence of the s1a genotype, compared to the s1b genotype in ulcer diseases, the presence of the s1a genotype had no predictive value because it was found in the majority of cases, irrespective of the clinical status. These results do not support the hypothesis⁸ that *H. pylori* strain possessing specific *vacA* gene is useful in predicting the risk for the development of a specific clinical

outcome, such as peptic ulcer diseases. Similar results were also reported by several investigators²³⁻²⁶. The reason for this difference on the preval-

ence of *vacA* s1 and/or the s1a alleles could be partly explained by genetic heterogeneity or structural differences in *H. pylori* populations throughout the world. Many studies confirmed that genomically different strains of *H. pylori* population appear to circulate in different geographic regions^{24,26,27}.

The positive rate for *cagA* gene in our study was 94.1% (128 out of 136). Only 8 (5.9%) patients were infected with *cagA*-negative strains of *H. pylori* (5 GU, 1 DU, and 2 CG). As we previously reported¹⁵, the present study also showed that the prevalence of *cagA* was not different between CG and GU or DU.

Several studies especially from Europe or the United States have still shown that *cagA* gene is significantly correlated with the development of peptic ulcer diseases and that *vacA* type s1 is also strongly associated with the presence of *cagA*^{21,22,28}. For example, van Doorn et al.²¹ reported that *H. pylori* strains which were typed as *vacA* s1/*cagA*⁺/*iceA* could be considered the most pathogenic and were found predominantly in patients with ulcer diseases. However, there have been increasing reports that the *cagA* gene may not be used as a discriminator of gastroduodenal diseases in the host because the prevalence of the *cagA* gene is very high irrespective of the clinical status and is not related to particular gastroduodenal diseases¹³⁻¹⁶.

The overall association of the *cagA* positive rate with *vacA* s1 allele in our study was similar with the reports from others. The association was even higher in Asian strains²⁵. However, *H. pylori* strains typed as the *cagA*⁺/*vacA* s1a were not found to be specifically associated with peptic ulcer diseases.

In conclusion, our data does not confirm the hypothesis that *H. pylori* strain possessing specific *vacA* gene is a marker to predict any specific gastroduodenal diseases in Korean patients.

Acknowledgement

The authors wish to acknowledge the financial support of the Korean Research Foundation made in the program of 1997.

REFERENCES

1. Graham DY, Malaty HM, Go MF. Are there susceptible hosts to *Helicobacter pylori* infection? *Scand J Gastroenterol Suppl* 205:6-10, 1994

2. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection. *Gut* 35:742-425, 1994
3. Malaty HM, Paykov V, Bykova O, Ross A, Graham DP, Anneger JF, Graham DY. *Helicobacter pylori* and socioeconomic factors in Russia. *Helicobacter* 1:82-87, 1996
4. Covacci A, Censini S, Bugnoli M, Petracca R, Buroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N. Molecular characterization of the 28-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci USA* 90: 5791-5795, 1993
5. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with *Helicobacter pylori* strains possessing *cagA* is associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res* 55:2111-2155, 1995
6. Labigne A, de Reuse H. Determinants of *Helicobacter pylori* pathogenicity. *Infect Agents Dis* 5:191-202, 1996
7. Kulpers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. *Helicobacter pylori* and atrophic gastritis: importance of the *cagA* status. *J Natl Cancer Inst* 87:1777-1780, 1995
8. Atherton JC, Peek RMJ, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* 112:92-99, 1997
9. Atherton JC. The clinical relevance of strain types of *Helicobacter pylori*. *Gut* 40:701-703, 1997
10. Cover TL, Dookey CP, Blaser MJ. Characterization of and human serologic response to proteins in *Helicobacter pylori* broth culture supernatants with vacuolating cytotoxin activity. *Infect Immun* 58:603-610, 1990
11. Peek RMJ, Miller GG, Tham KT, Perez-Perez GI, Atherton JC, Blaser MJ. Heightened cytokine expression and inflammatory response in vivo to *cagA*⁺ *Helicobacter pylori* strains. *Lab Invest* 73:760-770, 1995
12. Censini S, Lange C, Xiang Z, Crabtree JE, Ghara P, Borodovsky M, Rappuoli R, Covacci A. *cag*, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci USA* 93:4648-4653, 1996
13. Shimoyama T, Fukuda S, Tanaka M, Mikami T, Saito Y, Munakata A. High prevalence of the *cagA*-positive *Helicobacter pylori* strains in Japanese asymptomatic patients and gastric cancer patients. *Scand J Gastroenterol* 32:465-468, 1997
14. Pan ZJ, van der Hulst RWM, Feller M, Xiao SD, Tytgat GN, Dankert J, van der Ende A. Equally high prevalence of infection with *cagA*-positive *Helicobacter pylori* in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. *J Clin Microbiol* 35:100-103, 1997

- obiol* 35:1344-1347, 1997
15. Park SM, Park J, Kim JG, Cho JH, Lee DH, Cha YJ. Infection with *Helicobacter pylori* expressing the *cagA* gene is not associated with an increased risk of developing peptic ulcer diseases in Korean patients. *Scand J Gastroenterol* 33:923-927, 1998
 16. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, Shiratori Y, Omatu M. Major virulence factors, *vacA* and *cagA*, are commonly positive in *Helicobacter pylori* isolates in Japan. *Gut* 42:338-343, 1998
 17. Cover TL, Tummuru MKR, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among *Helicobacter pylori* strains. *J Biol Chem* 269:10566-10573, 1994
 18. Telford JL, Ghara P, De'Orco M, Comanducci M, Burroni D, Bugnoli M, Tecce MF, Censini S, Covacci A, Xiang Z. Gene structure of the *Helicobacter pylori* cytotoxin and evidence of its key role in gastric diseases. *J Exp Med* 179:1653-1658, 1994
 19. Atherton JC, Cao P, Peek RM, Tummuru MKR, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*: association of specific *vacA* types with cytotoxin production and peptic ulceration. *J Biol Chem* 270:17771-17777, 1995
 20. Queiroz DMM, Mendes EN, Rocha GA, Oliveira AMR, Moura SB, Lima Jr. GF, Oliveira CA. Gastric carcinoma (GC) strains of *H. pylori* (HP) present *vacA* sequence that allows to differentiate them from duodenal ulcer (DU) and chronic gastritis (CG) strains. *Gut* 39(Suppl 3):A66, 1996
 21. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W, Quint W. Clinical relevance of the *cagA*, *vacA*, and *iceA* status of *Helicobacter pylori*. *Gastroenterology* 115:58-66, 1998
 22. Strobel S, Bereswill S, Balig P, Allgaier P, Sonntag HG, Kist M. Identification and analysis of a new *vacA* genotype variant of *Helicobacter pylori* in different patient groups in Germany. *Clin Microbiol* 36:1285-1289, 1998
 23. Ito Y, Azuma T, Ito S, Miyaji H, Hirai M, Yamazaki Y, Sato F, Kato Y, Kuriyama M. Analysis and typing of the *vacA* gene from *cagA*-positive strains of *Helicobacter pylori* isolated in Japan. *J Clin Microbiol* 35:1710-1714, 1997
 24. Go MF, Cisse L, Graham DY. Failure to confirm association of *vacA* gene mosaicism with duodenal ulcer disease. *Scand J Gastroenterol* 132-136, 1998
 25. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relationship of *vacA* genotypes of *Helicobacter pylori* to *cagA* status, cytotoxin production, and clinical outcome. *Helicobacter* 3:241-253, 1998
 26. Wang HJ, Kuo CH, Yeh AA, Chang PC, Wang WC. Vacuolating toxin production in clinical isolates of *Helicobacter pylori* with different *vacA* genotypes. *J Infect Dis* 178:207-212, 1998
 27. van Doorn LJ, Figueiredo C, Megraud F, Pena S, Midolo P, Queiroz DMM, Carneiro F, Vanderborgt B, Pegado MGF, Sanna R, de Boer W, Schneeberger PM, Correa P, Enders KWNG, Atherton J, Blaser MJ, Quint W. Geographic distribution of *vacA* allelic types of *Helicobacter pylori*. *Gastroenterology* 116:823-830, 1999
 28. Rudi J, Kolb C, Nairwald M, Kuck D, Sieg A, Galle PR, Stremmel W. Diversity of *Helicobacter pylori vacA* and *cagA* genes and relationship to *VacA* and *CagA* protein expression, cytotoxin production and associated diseases. *J Clin Microbiol* 36:944-948, 1998
-